Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,032 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Human placental cells are resistant to SARS-CoV-2 infection and replication.
Yoshida N, Thomas JR, Appios A, Brember MP, Aye ILMH, Edgar JR, Firth AE, Chung BYW, McGovern N, Stewart H. Yoshida N, et al. Among authors: thomas jr. Wellcome Open Res. 2024 Nov 22;9:209. doi: 10.12688/wellcomeopenres.20514.2. eCollection 2024. Wellcome Open Res. 2024. PMID: 39640372 Free PMC article.
Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor Trials.
Sherry AD, Lin TA, McCaw ZR, Beck EJ, Kouzy R, Abi Jaoude J, Passy AH, Miller AM, Kupferman GS, Fuller CD, Thomas CR Jr, Koay EJ, Tang C, Msaouel P, Ludmir EB. Sherry AD, et al. Among authors: thomas cr jr. Int J Radiat Oncol Biol Phys. 2024 Dec 1;120(5):1239-1244. doi: 10.1016/j.ijrobp.2024.05.033. Epub 2024 Sep 30. Int J Radiat Oncol Biol Phys. 2024. PMID: 39352322
Author Correction: DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance.
Schröder M, Renatus M, Liang X, Meili F, Zoller T, Ferrand S, Gauter F, Li X, Sigoillot F, Gleim S, Stachyra TM, Thomas JR, Begue D, Khoshouei M, Lefeuvre P, Andraos-Rey R, Chung B, Ma R, Pinch B, Hofmann A, Schirle M, Schmiedeberg N, Imbach P, Gorses D, Calkins K, Bauer-Probst B, Maschlej M, Niederst M, Maher R, Henault M, Alford J, Ahrne E, Tordella L, Hollingworth G, Thomä NH, Vulpetti A, Radimerski T, Holzer P, Carbonneau S, Thoma CR. Schröder M, et al. Among authors: thomas jr. Nat Commun. 2024 Aug 19;15(1):7109. doi: 10.1038/s41467-024-51317-6. Nat Commun. 2024. PMID: 39160182 Free PMC article. No abstract available.
Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials.
Sherry AD, Lin TA, McCaw ZR, Beck EJ, Kouzy R, Abi Jaoude J, Passy AH, Miller AM, Kupferman GS, Fuller CD, Thomas CR Jr, Koay EJ, Tang C, Msaouel P, Ludmir EB. Sherry AD, et al. Among authors: thomas cr jr. Int J Cancer. 2024 Dec 1;155(11):1939-1943. doi: 10.1002/ijc.35129. Epub 2024 Aug 13. Int J Cancer. 2024. PMID: 39138841
Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation.
Lin TA, McCaw ZR, Koong A, Lin C, Abi Jaoude J, Patel R, Kouzy R, El Alam MB, Sherry AD, Noticewala SS, Fuller CD, Thomas CR Jr, Sun R, Lee JJ, Lin R, Yuan Y, Shyr Y, Meirson T, Ludmir EB. Lin TA, et al. Among authors: thomas cr jr. Clin Cancer Res. 2024 Oct 15;30(20):4791-4799. doi: 10.1158/1078-0432.CCR-24-0566. Clin Cancer Res. 2024. PMID: 39133081
2,032 results